ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Study of Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients Treated With Venetoclax in Greece
- Conditions
- Chronic Lymphocytic Leukemia
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 180
- Registration Number
- NCT04159779
- Locations
- 🇬🇷
University Gen Hosp of Patra /ID# 212914, Patras, Greece
🇬🇷General Hospital of Chania "Agios Georgios" /ID# 241685, Chania, Greece
🇬🇷Papageorgiou General Hospital /ID# 213710, Thessaloniki, Greece
A Study of Women Receiving Standard of Care (SOC) for the Treatment of Pelvic Pain Due to Suspected or Confirmed Endometriosis and the Impact on the Disease or Symptom Progression.
- Conditions
- DysmenorrheaEndometriosisChronic Pelvic Pain
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 291
- Registration Number
- NCT04140175
- Locations
- 🇺🇸
Capital Women's Care - Hagerstown /ID# 217984, Hagerstown, Maryland, United States
🇺🇸Stamford Hospital /ID# 216975, Stamford, Connecticut, United States
🇺🇸Agile Clinical Research Trials /ID# 217762, Atlanta, Georgia, United States
A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinavir/Ritonavir (LPV/r) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients After Switching From Kaletra in the Routine Clinical Settings of Russian Federation
- Conditions
- HIV-1 Infection
- First Posted Date
- 2019-10-24
- Last Posted Date
- 2021-07-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 239
- Registration Number
- NCT04138199
- Locations
- 🇷🇺
GBUZ Regional Center for the P /ID# 216293, Ekaterinburg, Russian Federation
🇷🇺Rep Center for the Prev and Control of AIDS and Inf Dis of the MoH of Chuvashia /ID# 216479, Cheboksary, Russian Federation
🇷🇺Reg Ctr for AIDS /ID# 216288, Chelyabinsk, Russian Federation
A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's Disease
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2021-12-15
- Lead Sponsor
- AbbVie
- Registration Number
- NCT04127695
- Locations
- 🇺🇸
University of Florida - Archer /ID# 212823, Gainesville, Florida, United States
🇺🇸Evergreen Neuroscience Institute /ID# 212827, Kirkland, Washington, United States
🇺🇸Columbia Univ Medical Center /ID# 212826, New York, New York, United States
A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab
- First Posted Date
- 2019-09-25
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 244
- Registration Number
- NCT04102007
- Locations
- 🇬🇧
Northern Care Alliance NHS Group /ID# 213873, Salford, United Kingdom
🇺🇸Burke Pharmaceutical Research /ID# 225023, Hot Springs, Arkansas, United States
🇺🇸Arkansas Research Trials /ID# 225497, North Little Rock, Arkansas, United States
A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2019-09-25
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 112
- Registration Number
- NCT04102020
- Locations
- 🇺🇸
The John Theurer Cancer /ID# 215191, Hackensack, New Jersey, United States
🇺🇸University of California, Los Angeles /ID# 219149, Los Angeles, California, United States
🇺🇸Duplicate_Rush University Medical Center /ID# 218815, Chicago, Illinois, United States
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2019-09-11
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 218
- Registration Number
- NCT04086264
- Locations
- 🇺🇸
City of Hope National Medical Center /ID# 269273, Duarte, California, United States
🇺🇸University Of California Irvine Medical Center /ID# 269275, Orange, California, United States
🇺🇸Moffitt Cancer Center /ID# 269269, Tampa, Florida, United States
Real-World Experience Study of Elagolix For the Treatment of Endometriosis in Canada
- Conditions
- Endometriosis
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 100
- Registration Number
- NCT04080856
- Locations
- 🇨🇦
IWK Health Center /ID# 213066, Halifax, Nova Scotia, Canada
🇨🇦Strand Clinic /ID# 213567, St. John's, Newfoundland and Labrador, Canada
🇨🇦Jessima R&D Inc. /ID# 212943, Lasalle, Quebec, Canada
BOTOX® Treatment for Adults With a Wide Lower Face Due to Masseter Muscle Prominence
- Conditions
- Masseter Muscle Prominence
- Interventions
- Other: Placebo
- First Posted Date
- 2019-08-29
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 377
- Registration Number
- NCT04073303
- Locations
- 🇨🇳
Tri-Service General Hospital /ID# 233080, Taipei City, Taiwan
🇨🇦Duplicate_Beacon Dermatology Inc /ID# 233018, Calgary, Alberta, Canada
🇨🇦Duplicate_Humphrey Cosmetic Dermatology /ID# 232764, Vancouver, British Columbia, Canada
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)
- Conditions
- Chronic Kidney Disease (CKD)Secondary Hyperparathyroidism (SHPT)
- Interventions
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 16
- Registration Number
- NCT04064827
- Locations
- 🇺🇸
Augusta University Medical Center /ID# 252149, Augusta, Georgia, United States
🇺🇸Arkansas Children's Hospital /ID# 225417, Little Rock, Arkansas, United States
🇺🇸Stanford University /ID# 252150, Redwood City, California, United States